Stuart Brown

Stuart Brown

Auto-generated profile, based on publicly available information

Stuart Brown

Division of Retrovirology, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Bone
Verified
Journal Article
Closed access
NKNupur Kohli
Nupur Kohli
SHSonia Ho
Sonia Ho
SBStuart J. Brown
Stuart J. Brown
PSPrasad Sawadkar
Prasad Sawadkar
VSVaibhav Sharma
Vaibhav Sharma
EGElena García-Gareta
Elena García-Gareta

1 April 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
ANAishath S. Naeem
Aishath S. Naeem
CTCristina Tommasi
Cristina Tommasi
CCChristian Cole
Christian Cole
SBStuart J. Brown
Stuart J. Brown
YZYanan Zhu
Yanan Zhu
RORyan O'Shaughnessy
Ryan O'Shaughnessy
Filaggrin, which is encoded by the filaggrin gene (FLG), is an important component of the skin's barrier to the external environment, and genetic defects in FLG strongly associate with atopic dermatitis (AD). However, not all patients with AD have FLG mutations. We hypothesized that these patients might possess other defects in filaggrin expression and processing contributing to barrier disruption and AD, and therefore we present novel therapeutic targets for this disease. We describe the relationship between the mechanistic target of rapamycin complex 1/2 protein subunit regulatory associated protein of the MTOR complex 1 (RAPTOR), the serine/threonine kinase V-Akt murine thymoma viral oncogene homolog 1 (AKT1), and the protease cathepsin H (CTSH), for which we establish a role in filaggrin expression and processing. Increased RAPTOR levels correlated with decreased filaggrin expression in patients with AD. In keratinocyte cell cultures RAPTOR upregulation or AKT1 short hairpin RNA knockdown reduced expression of the protease CTSH. Skin of CTSH-deficient mice and CTSH short hairpin RNA knockdown keratinocytes showed reduced filaggrin processing, and the mouse had both impaired skin barrier function and a mild proinflammatory phenotype. Our findings highlight a novel and potentially treatable signaling axis controlling filaggrin expression and processing that is defective in patients with AD.

1 September 2008 in Journal of General Virology
Verified
Journal Article
Open access
NBNeil Berry
Neil Berry
RSRichard Stebbings
Richard Stebbings
DFDebbie Ferguson
Debbie Ferguson
CHClaire Ham
Claire Ham
JAJack Alden
Jack Alden
NANeil Almond
Neil Almond
Vaccination with live attenuated simian immunodeficiency virus (SIVmacC8) confers potent, reproducible protection against homologous wild-type virus challenge (SIVmacJ5). The ability of SIVmacC8 to confer resistance to superinfection with an uncloned ex vivo derivative of SIVmac251 (SIVmac32H/L28) was investigated. In naïve, Mauritian-derived cynomolgus macaques (Macaca fascicularis), SIVmac32H/L28 replicated to high peak titres (>108 SIV RNA copies ml−1), persisted at high levels and induced distinctive pathology in lymphoid tissues. In cynomolgus macaques vaccinated with SIVmacC8, no evidence of detectable superinfection was observed in 3/8 vaccinates following challenge 3 or 20 weeks later with SIVmac32H/L28. Analyses after SIVmac32H/L28 challenge revealed a significant reduction in viral RNA (P99 % sequence similarity with the vaccine virus. Highly sensitive PCR assays that distinguish vaccine and challenge virus stocks demonstrated restimulation of replication of the vaccine virus SIVmacC8 in the face of potent protection against a vigorous, homologous challenge virus. Vaccine-induced antiviral neutralizing antibodies and anti-Nef CD8+ cytotoxic T cell responses did not correlate with the outcome of the challenge. Defining the mechanism of vaccine protection will need to account for the effective control of a genetically closely related challenge virus whilst remaining unable to suppress replication of the pre-existing vaccine virus. The role of innate and intrinsic anti-retroviral immunity in the protection conferred by live attenuated SIV vaccines warrants careful study.

1 October 2005 in Journal of Virology
Verified
Journal Article
Open access
PDF file
RSRichard Stebbings
Richard Stebbings
NBNeil Berry
Neil Berry
HWHerman Waldmann
Herman Waldmann
PBPru Bird
Pru Bird
GHGeoff Hale
Geoff Hale
NANeil Almond
Neil Almond
In order to test the hypothesis that CD8 + cytotoxic T lymphocytes mediate protection against acute superinfection, we depleted >99% of CD8 + lymphocytes in live attenuated simian immunodeficiency virus macC8 (SIVmacC8) vaccinees from the onset of vaccination, maintained that depletion for 20 days, and then challenged with pathogenic, wild-type SIVmacJ5. Vaccinees received 5 mg per kg of humanized anti-CD8 monoclonal antibody (MAb) 1 h before inoculation, followed by the same dose again on days 3, 7, 10, 13, and 17. On day 13, peripheral CD8 + T lymphocytes were >99% depleted in three out of four anti-CD8 MAb-treated vaccinees. At this time attenuated SIVmacC8 viral RNA loads in anti-CD8 MAb-treated vaccinees were significantly higher than control vaccinees treated contemporaneously with nonspecific human immunoglobulin. Lymphoid tissue CD8 + T lymphocyte depletion was >99% in three out of four anti-CD8 MAb-treated vaccinees on the day of wild-type SIVmacJ5 challenge. All four control vaccinees and three out of four anti-CD8 MAb-treated vaccinees were protected against detectable superinfection with wild-type SIVmacJ5. Although superinfection with wild-type SIVmacJ5 was detected at postmortem in a single anti-CD8 MAb-treated vaccinee, this did not correlate with the degree of preceding CD8 + T lymphocyte depletion. Clearance of attenuated SIVmacC8 viremia coincided with recovery of normal CD8 + T lymphocyte counts between days 48 and 76. These results support the view that cytotoxic T lymphocytes are important for host-mediated control of SIV primary viremia but do not indicate a central role in protection against acute superinfection conferred by inoculation with live attenuated SIV.

1 December 2004 in Virology
Verified
Journal Article
Closed access
RSRichard Stebbings
Richard Stebbings
NBNeil Berry
Neil Berry
JSJim Stott
Jim Stott
RHRobin Hull
Robin Hull
BWBarry Walker
Barry Walker
NANeil Almond
Neil Almond

1 December 2011 in Microbial Pathogenesis
Verified
Journal Article
Closed access
DRDurga Reddi
Durga Reddi
SBStuart J. Brown
Stuart J. Brown
Georgios BelibasakisGeorgios Belibasakis
Georgios Belibasakis